What’s Infinity Pharmaceuticals Incorporated (NASDAQ:INFI) Upside After This Short Interest Decrease?

January 22, 2018 - By Linda Rogers

 What's Infinity Pharmaceuticals Incorporated (NASDAQ:INFI) Upside After This Short Interest Decrease?

Investors sentiment decreased to 0.47 in 2017 Q3. Its down 0.16, from 0.63 in 2017Q2. It turned negative, as 15 investors sold Infinity Pharmaceuticals, Inc. shares while 23 reduced holdings. 6 funds opened positions while 12 raised stakes. 27.30 million shares or 18.05% less from 33.31 million shares in 2017Q2 were reported.
California Employees Retirement has 88,100 shares for 0% of their portfolio. Guggenheim Cap Llc reported 15,080 shares or 0% of all its holdings. Germany-based Deutsche National Bank Ag has invested 0% in Infinity Pharmaceuticals, Inc. (NASDAQ:INFI). Bogle Invest Mgmt L P De reported 224,793 shares or 0.02% of all its holdings. Meeder Asset Mngmt has invested 0% in Infinity Pharmaceuticals, Inc. (NASDAQ:INFI). Aperio Limited holds 0% or 11,161 shares. Grp Incorporated One Trading L P, Illinois-based fund reported 15,072 shares. Morgan Stanley invested in 84,370 shares or 0% of the stock. Orbimed Advisors Limited Liability owns 2.21M shares. Jpmorgan Chase Comm has invested 0% in Infinity Pharmaceuticals, Inc. (NASDAQ:INFI). Bnp Paribas Arbitrage Sa accumulated 1,755 shares. Amer Finance Gp owns 40,000 shares or 0.01% of their US portfolio. Jacobs Levy Equity has invested 0% of its portfolio in Infinity Pharmaceuticals, Inc. (NASDAQ:INFI). Pub Employees Retirement Association Of Colorado stated it has 14,533 shares or 0% of all its holdings. Blackrock owns 1.01M shares or 0% of their US portfolio.

Since October 3, 2017, it had 1 insider buy, and 0 selling transactions for $2.01 million activity.

The stock of Infinity Pharmaceuticals Incorporated (NASDAQ:INFI) registered a decrease of 8.93% in short interest. INFI’s total short interest was 1.80M shares in January as published by FINRA. Its down 8.93% from 1.98M shares, reported previously. With 454,300 shares average volume, it will take short sellers 4 days to cover their INFI’s short positions. The short interest to Infinity Pharmaceuticals Incorporated’s float is 4.56%.

The stock increased 0.49% or $0.01 during the last trading session, reaching $2.04. About 340,615 shares traded. Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) has declined 60.96% since January 22, 2017 and is downtrending. It has underperformed by 77.66% the S&P500.

Infinity Pharmaceuticals, Inc., a biopharmaceutical company, develops medicines for patients with difficult-to-treat diseases in the United States. The company has market cap of $103.45 million. The Company’s lead product candidate includes IPI-549 an orally administered immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma is in Phase 1 clinical study. It currently has negative earnings. The firm has a license agreement with Verastem, Inc. to research, develop, commercialize, and manufacture duvelisib, a selective inhibitor of the PI3K delta and gamma isoforms, including DUO study that is in randomized Phase III clinical study for patients with relapsed/refractory chronic lymphocytic leukemia and products containing duvelisib; Intellikine, Inc. to discover, develop, and commercialize pharmaceutical products targeting the delta and/or gamma isoforms of PI3K; and Takeda Pharmaceutical Company Limited to develop and commercialize duvelisib.

Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) Ratings Coverage

Among 9 analysts covering Infinity Pharmaceutical (NASDAQ:INFI), 2 have Buy rating, 0 Sell and 7 Hold. Therefore 22% are positive. Infinity Pharmaceutical had 16 analyst reports since August 7, 2015 according to SRatingsIntel. RBC Capital Markets maintained Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) rating on Friday, August 7. RBC Capital Markets has “Outperform” rating and $15 target. The firm has “Outperform” rating by Wells Fargo given on Thursday, October 12. FBR Capital initiated Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) on Wednesday, March 2 with “Outperform” rating. The stock has “Neutral” rating by Wedbush on Tuesday, June 14. The firm earned “Sector Perform” rating on Wednesday, June 15 by RBC Capital Markets. The rating was downgraded by Morgan Stanley on Wednesday, June 15 to “Equal-Weight”. The firm has “Market Perform” rating by Wells Fargo given on Wednesday, June 15. The company was maintained on Wednesday, March 9 by JMP Securities. Wedbush maintained the stock with “Neutral” rating in Thursday, February 25 report. The stock has “Market Perform” rating by William Blair on Wednesday, June 15.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: